Molecular structure of Sipoglitazar, CAS Number: 342026-92-0
Sipoglitazar (CAS 342026-92-0)
Alternate Names:
3-[3-Ethoxy-1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic Acid
Application:
Sipoglitazar is shows agonistic activities on the human peroxisome proliferator-activated receptors
CAS Number:
342026-92-0
Molecular Weight:
463.55
Molecular Formula:
C25H25N3O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sipoglitazar is a novel antidiabetic agent due to its agonistic activities on the three human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ
Sipoglitazar (CAS 342026-92-0) References
- Discontinued drugs in 2006: renal, endocrine and metabolic drugs. | Colca, JR. 2007. Expert Opin Investig Drugs. 16: 1517-23. PMID: 17922617
- An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide. | Nishihara, M., et al. 2012. Drug Metab Dispos. 40: 249-58. PMID: 22028317
- Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -Δ, in rats and monkeys and comparison with humans in vitro. | Nishihara, M., et al. 2012. Drug Metab Pharmacokinet. 27: 223-31. PMID: 22123126
- Modeling of red blood cell life-spans in hematologically normal populations. | Lledó-García, R., et al. 2012. J Pharmacokinet Pharmacodyn. 39: 453-62. PMID: 22847734
- The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. | Stringer, F., et al. 2013. Eur J Clin Pharmacol. 69: 423-30. PMID: 22960998
- Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar. | Stringer, F., et al. 2013. J Clin Pharmacol. 53: 256-63. PMID: 23444281
- UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation. | Nishihara, M., et al. 2013. Drug Metab Pharmacokinet. 28: 475-84. PMID: 23648677
- A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar. | Stringer, F., et al. 2014. J Clin Pharmacol. 54: 453-61. PMID: 24214217
- Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. | Daniels, MA., et al. 2016. Pharmacogenomics J. 16: 399-410. PMID: 27432533
- Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. | Lu, Y., et al. 2017. Eur J Clin Pharmacol. 73: 307-315. PMID: 27900402
- Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). | Ma, Y., et al. 2017. J Med Chem. 60: 8691-8705. PMID: 28653847
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. | Hong, F., et al. 2018. Int J Mol Sci. 19: PMID: 30060458
- The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation. | Kalliora, C. and Drosatos, K. 2020. J Cardiovasc Pharmacol. 76: 514-526. PMID: 33165133
- The structural basis of conserved residue variant effect on enzyme activity of UGT2B15. | Zhang, L., et al. 2023. Biochim Biophys Acta Proteins Proteom. 1871: 140888. PMID: 36610584
Activator of:
PPAR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sipoglitazar, 0.5 mg | sc-472915 | 0.5 mg | $430.00 |